viewJohnson & Johnson

US prepares for potential human challenge study for COVID-19 vaccine

Government researchers are developing a strain of the virus that would be used in trials where healthy participants get infected

Johnson & Johnson - US prepares for potential human challenge study for COVID-19 vaccine

The US is preparing for a potential human challenge study for COVID-19 vaccines.

Government researchers are developing a strain of the coronavirus that would be used in these trials, where healthy participants are vaccinated then exposed to the virus to get infected.

READ: Why do vaccine trials take so long?

Usually, volunteers participating in vaccine trials are not asked to catch the virus, especially if there are many cases like in the current pandemic. This is why trials last for months.

“Should there be a need for human challenge studies to fully assess candidate vaccines or therapeutics for SARS-CoV-2, NIAID has begun investigations of the technical and ethical considerations of conducting human challenge studies,” the US National Institute of Allergy and Infectious Diseases told Reuters.

The trials would be conducted in small numbers and isolation units to control the disease, while those involving over 100 people would be done in multiple locations.

Johnson & Johnson (NYSE:JNJ) and AstraZeneca PLC (LON:AZN), which are also developing vaccine candidates, previously said they would consider these trials if needed.

Open Orphan PLC’s (LON:ORPH) hVIVO arm is set to start phase I of a human challenge trial for a nasal vaccine for coronavirus in the autumn.

It will quarantine 48 healthy young adults at a facility in London’s Whitechapel to assess whether the drug provokes an immune response.

Quick facts: Johnson & Johnson

Price: 145.66 USD

Market: NYSE
Market Cap: $383.5 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


GinsGlobal Managing Director sees Healthcare and Healthcare innovation as...

HANetf and GinsGlobal Index Funds' Managing Director Anthony Ginsberg joined Steve Darling from Proactive to share details about the success of their Healthcare Innovations ETF. Ginsberg discusses how COVID-19 had made a direct impact on that fund, especially in the telemedicine...

11 hours, 34 minutes ago

2 min read